Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619843 | 0.87 | KMT2A (0.51) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL1665229 | 0.81 | DAO (0.58) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL163302 | 0.79 | KMT2A (0.54) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL1423671 | 0.79 | KMT2A (0.54) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL1007015 | 0.79 | MAPK1 (0.61) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL5561961 | 0.79 | KMT2A (0.48) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL21810849 | 0.79 | POLB (0.45) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL21810887 | 0.79 | KMT2A (0.45) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL21607841 | 0.79 | HCAR2 (0.66) | KMT2AL3MBTL1NPSR1POLBTHRB | |
| SCHEMBL17593217 | 0.78 | KMT2A (0.52) | KMT2AL3MBTL1NPSR1POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| WO-2021026672-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | KMT2A 328/4885L3MBTL1 1713/4885NPSR1 4341/4885 |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | ABCB1, CYP3A43, CYP3A5 | KMT2A 4685/4885L3MBTL1 4385/4885NPSR1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.